- Conditions
- Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
- Interventions
- FDC macitentan/tadalafil, Macitentan 10 mg, Tadalafil 40 mg, Placebo FDC, Placebo macitentan, Placebo tadalafil
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 26
- States / cities
- Fullerton, California • Los Angeles, California • Atlanta, Georgia + 22 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 110
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hypertension
- Interventions
- Nebivolol, Valsartan and Hydrochlorothiazide
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 812 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 135
- States / cities
- Birmingham, Alabama • Foley, Alabama • Gulf Shores, Alabama + 113 more
- Conditions
- Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT)
- Interventions
- Latanoprost, Arm 2, Latanoprost SR insert
- Drug
- Lead sponsor
- Daniel Moore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa, Vision Disorders, Acute Coronary Syndrome, Implantable Defibrillator User, Congestive Heart Failure, Hypertrophic Obstructive Cardiomyopathy, Orthostatic Hypotension, Syncope, Presyncope, Narcolepsy, Dementia, Multiple Sclerosis, Parkinson Disease, Brain Injuries, Spinal Cord Injuries, Stroke, Vertigo, Dizziness, Seizures, Substance Use, Insulin Dependent Diabetes Mellitus, Arthritis, Foot--Abnormalities, Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea, End Stage Renal Disease, Sleep Apnea, Insomnia, Restless Legs Syndrome
- Interventions
- Driving Decision Aid, Older Drivers Website
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 529 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 3
- States / cities
- La Jolla, California • Aurora, Colorado • Indianapolis, Indiana
- Conditions
- Glaucoma, Open-Angle, Ocular Hypertension
- Interventions
- OT-730 ophthalmic solution, timolol maleate ophthalmic solution, OT-730 placebo
- Drug
- Lead sponsor
- Othera Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 5
- States / cities
- Artesia, California • Roswell, Georgia • Charlotte, North Carolina + 2 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- RVT-1201, Placebo
- Drug
- Lead sponsor
- Altavant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Sacramento, California • Santa Barbara, California + 17 more
- Conditions
- Hypertension
- Interventions
- Amlodipine 5 mg, Placebo, Telmisartan 20 mg, Telmisartan 40 mg, Amlodipine 10 mg, Telmisartan 80 mg, Amlodipine 2.5 mg
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,461 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 101
- States / cities
- Fairhope, Alabama • Huntsville, Alabama • Chandler, Arizona + 81 more
- Conditions
- Essential Hypertension
- Interventions
- Aprocitentan 5 mg, Aprocitentan 10 mg, Aprocitentan 25 mg, Aprocitentan 50 mg, Lisinopril 20 mg, Placebo
- Drug
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,659 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 74
- States / cities
- Fort Payne, Alabama • Chandler, Arizona • Peoria, Arizona + 62 more
- Conditions
- Uncontrolled Stage 2 Hypertension
- Interventions
- Renal denervation
- Device
- Lead sponsor
- SoniVie Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 6 more
- Conditions
- Hypertension
- Interventions
- Low-fat dairy
- Other
- Lead sponsor
- Dairy Research Institute
- Other
- Eligibility
- 20 Years to 69 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Glen Ellyn, Illinois
- Conditions
- Hypertension
- Interventions
- Telmisartan, Ramipril
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 70
- States / cities
- Glendale, Arizona • Tempe, Arizona • Tucson, Arizona + 58 more
- Conditions
- Hypertension
- Interventions
- Iyengar yoga, Enhanced nutritional care classes
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
- Interventions
- Ralinepag, Placebo
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 687 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 68
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
- Conditions
- Glaucoma, Ocular Hypertension
- Interventions
- latanoprost
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 0 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 6
- States / cities
- Artesia, California • Atlanta, Georgia • North Dartmouth, Massachusetts + 2 more
- Conditions
- Symptomatic Neurogenic Orthostatic Hypertension, nOH
- Interventions
- Ampreloxetine <Dose A>, Ampreloxetine <Dose B>, Ampreloxetine Placebo, Moxifloxacin, Moxifloxacin Placebo
- Drug
- Lead sponsor
- Theravance Biopharma
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Open-angle Glaucoma
- Interventions
- ANX007
- Biological
- Lead sponsor
- Annexon, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Overweight , Obesity, Class I Obesity
- Interventions
- Low-processed DGA Diet, Ultra-processed DGA Diet
- Other
- Lead sponsor
- USDA Grand Forks Human Nutrition Research Center
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Grand Forks, North Dakota
- Conditions
- Hypertension
- Interventions
- baxdrostat
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Hypertension in Pregnancy
- Interventions
- Labetalol or Nifedipine
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 14 Years to 89 Years · Female only
- Enrollment
- 74 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Treprostinil Inhalation Powder
- Drug
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Pulmonary Arterial Hypertension PAH
- Interventions
- Placebo Cohort 1 (1.5 mg/kg/dose) only, ZMA001 (BC-NKA-20008)
- Other · Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Open-angle Glaucoma
- Interventions
- PER-001 Intravitreal Implant - Low Dose, PER-001 Intravitreal Implant - High Dose, PER-001 Intravitreal Implant - Sham
- Drug
- Lead sponsor
- Perfuse Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Hypertension
- Interventions
- Nebivolol, Metoprolol ER (TM)
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hypertension
- Interventions
- Concord Grape Juice
- Dietary Supplement
- Lead sponsor
- Boston University
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts